Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dapagliflozin in Respiratory Failure in Patients With COVID-19
NCT04350593Phase 3Completed
- Sponsor
- Saint Luke's Health System
- Start
- Apr 2020
- Primary completion
- Mar 2021
- Modality
- Small Molecules
- Countries
- 7
01
Overview
A Phase 3 trial of dapagliflozin in coronavirus disease 2019 (COVID-19), sponsored by Saint Luke's Health System. Started Apr 2020; status: completed.
02
Drugs
dapagliflozin
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04350593.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04350593.